VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NBIX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NBIXNeurocrine Biosciences, Inc.
$165.92$16.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
NBIX logo

Neurocrine Biosciences, Inc.

NBIX
NASDAQ · Neuroscience Biotech
$165.92
At close - Nov 17, 4:00 PM EST - USD
Market Cap$16.68B
P/E24.8x
52W High$186.12
Volume1.04M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Commercial Growth Outpaces Margin Gains at Neurocrine

Neurocrine's revenue rose 41.2% year over year to $1.1B in 2026Q3 after 39.5% growth in Q2, suggesting durable commercial momentum, while operating margin expanded from 22.6% in 2024Q4 to 29.5% in 2026Q3 and free cash flow reached $383.6M in the latest quarter.

GrowthExpanding
ProfitabilityStrong
ValuationReview
TechnicalsNeutral
Explore valuation models
MARKET ACTION

NBIX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-27% Peers

P/E is 27% below peer median

03

Market leadership

RS 78 · Avg

Average momentum (RS Rating: 78)

04

Trend Check

N/A

Trend data unavailable

Next CatalystEstimated earnings · Feb 2
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue and operating margin have improved strongly, with quarterly revenue reaching $1.1B and operating margin rising to 29.5% in 2026Q3, although the trend has been volatile, with margin dipping to 4.1% in 2025Q1.

Analyst Consensus+22.6% target
Buy(37 analysts)
32 Buy5 Hold0 Sell

The Bull Case

Upside Catalysts

CRENESSITY clinical data

Neurocrine Biosciences presented a retrospective case series of CRENESSITY for patients with classic congenital adrenal hyperplasia, showcasing potential therapeutic benefits.

Analyst coverage and targets

MarketBeat and other platforms provide stock analysis, price targets, and earnings estimates for NBIX, indicating strong institutional interest.

Pipeline expansion potential

The presentation of CRENESSITY at ENDO 2026 highlights Neurocrine's ongoing pipeline development and potential for future growth.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
NBIX+18.01%
S&P 500 (^GSPC)+7.21%
1-Year Return
NBIX+15.58%
S&P 500 (^GSPC)+10.03%
3-Year Return
NBIX+52.30%
S&P 500 (^GSPC)+62.71%
5-Year Return
NBIX+85.18%
S&P 500 (^GSPC)+54.53%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
24.8x
Forward P/EExpansion
22.7x
EV/EBITDA0th %ile
17.0x
FCF YieldCash Flow
6.2%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
24.8x
53.3x
0th· Low
EV/EBITDA
17.0x
44.6x
0th· Low
Price/FCF
16.0x
35.8x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$83.99-49.4%
Base (Fair)$146.91-12.2%
Bull$197.69+19.1%
$83.99 Bear$146.91 Base$197.69 Bull
Current Market Price: $165.92
Trades at a 12.9% premium to Base DCF ($146.91)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$2.86B+21.4% YoY
Net income FY25
$479M+40.2% YoY
Free cash flow FY25
$749M+34.4% YoY
Operating margin FY25
21.6%-2.6 pts YoY
ROIC (FY25)16.1%
Avg ROIC 5Y11.8%
ROE (TTM)19.7%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 2, 2026
$3.29+72.3%
vs $1.91
$1.1B+7.6%
vs $1.0B
Q3 2026
Jul 30, 2026
$2.85+54.1%
vs $1.85
$959M+7.7%
vs $890M
Q2 2026
May 5, 2026
$1.91+56.6%
vs $1.22
$815M+6.0%
vs $768M
Q1 2026
Feb 11, 2026
$1.88+4.4%
vs $1.80
$806M+1.9%
vs $790M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·20h ago
Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Zacks Investment Research·2d ago
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Defense World·2d ago
Eurizon Capital SGR S.p.A. Sells 10,154 Shares of Neurocrine Biosciences, Inc. $NBIX

Eurizon Capital SGR S.p.A. trimmed its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 20.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,121 shares of the company's stock after selling 10,154 shares during the quarter. Eurizon Capital SGR

Zacks Investment Research·Nov 10, 2026
NBIX or GRDN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks presents investors with the better value opportunity right now?

Filtered for Neurocrine Biosciences, Inc.More Headlines
04

Compare before deciding

Benchmark NBIX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Neurocrine Biosciences, Inc. (NBIX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NBIX logoNBIXNeurocrine Biosciences, Inc.Current
$165.92$16.68B24.8521.45%18.98%19.74%—
INVA logoINVAInnoviva, Inc.
$18.30$1.35B6.8218.52%43.79%15.84%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$18.32$3.14B8.8711.87%30.13%28.03%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.36$5.01B-47.55114.51%-9.17%——
RARE logoRAREUltragenyx Pharmaceutical Inc.
$16.70$1.64B-3.2520.13%-71.78%——
PRGO logoPRGOPerrigo Company plc
$15.76$2.18B-1.24-2.75%-43.27%-68.13%7.3%

Compare NBIX vs Peers

Neurocrine Biosciences, Inc. (NBIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs INVA

Most directly comparable listed peer for NBIX.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare NBIX against a more recognizable public peer.

Peer Set

Compare Top 5

vs INVA, ACAD, PTCT, RARE

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

NBIX SEC Filings & Documents

Neurocrine Biosciences, Inc. (NBIX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 2, 2026·SEC

Material company update

Jul 30, 2026·SEC

Material company update

May 28, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 11, 2026·SEC

FY 2025

Feb 10, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 2, 2026·SEC

FY 2026

Jul 31, 2026·SEC

FY 2026

May 5, 2026·SEC

Get notified when NBIX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NBIX Frequently Asked Questions

Neurocrine Biosciences, Inc. (NBIX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Neurocrine Biosciences, Inc.'s revenue?

Neurocrine Biosciences, Inc. (NBIX) reported $3.70B in revenue over the trailing twelve months. Revenue was $2.86B in fiscal year 2025. That is 14798% more than the $19.2M of fiscal year 1996.

How fast is Neurocrine Biosciences, Inc. growing?

Neurocrine Biosciences, Inc. (NBIX) grew revenue by 38.0% over the trailing twelve months, compared with the twelve months before.

Is NBIX profitable?

Yes. Neurocrine Biosciences, Inc. (NBIX) earned $702.5M in net income over the trailing twelve months (a 19.0% net margin).

Dividend & Returns
What is NBIX's return on equity?

Neurocrine Biosciences, Inc. (NBIX) had a return on equity (ROE) of 19.7% over the trailing twelve months. That is above the market's typical 10-15%.

What is Neurocrine Biosciences, Inc.'s free cash flow?

Neurocrine Biosciences, Inc. (NBIX) generated $1.04B in free cash flow over the trailing twelve months.

What if you invested $1,000 in NBIX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →